NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1420.00 17.30 (1.23%)

563.1K NSE+BSE Volume

NSE 27 Aug, 2026 3:31 PM (IST)

114,715.2

Market Cap

High in industry

Beta 1Year

Very Low volatility

US FDA Observation

Cipla gets a Form 483 with 7 observations from the US FDA after a cGMP inspection at Pithampur unit See details

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Search Inside the pdf :

Cipla Ltd.

27 Jul 2026, 12:00AM

1420.00

1.23%

Outlook

Accumulate: Cipla Ltd.

Target

Deven Choksey

We expect Cipla to deliver sustainable long-term growth, supported by the continued strength of its India formulations business, an improving chronic therapy mix, and a robust branded franchise.

Number of FII/FPI investors decreased from 964 to 917 in Jun 2026 qtr

Cipla Ltd.

24 Jul 2026

1420.00

1.23%

A soft quarter; recovery hinges on timely launches in US

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Cipla’s muted performance in Q1FY27 was due to lower sales of gRevlimid, the discontinuation of lanreotide and a cost surge due to geopolitical tensions.

Cipla Ltd. is trading below its 30 day SMA of 1441.8

Cipla Ltd.

24 Jul 2026

1420.00

1.23%

Result Update:Cipla

Buy: Cipla Ltd.

Target

Axis Direct

BUY (maintained)

Cipla Ltd. is trading below its 30 day SMA of 1441.8

Cipla Ltd.

24 Jul 2026

1420.00

1.23%

grew just 3.5% YoY to 7077 crore mainly on the back of weak North America Business which de-grew 21% to 1532 crore. The weakness was on account of high base of gRevlimid and absence of anti-growth hormone drug Lanreotide. On the other hand, domestic formulations (One India) grew 12.4% to 3452 crore, Africa grew 12% to 977 crore, and RoW market grew 27% to 1317 crore. EBITDA de-grew ~33% YoY to 1192 crore with EBITDA margins of 16.7% down 881 bps; GPM declined by 626 bps and stood at 62.5%. PAT de-grew 39% to 786 crore....

Cipla Ltd. is trading above its 200 day SMA of 1396.7

Cipla Ltd.

23 Jul 2026

1420.00

1.23%

Operationally in-line 1Q; India delivers, US awaits revival

Neutral: Cipla Ltd.

Target

Motilal Oswal

Cipla delivered a largely in-line operational performance in 1QFY27. Earnings were better than expected due to higher other income for the quarter. India segment’s YoY growth has been on an uptrend for the fourth
consecutive quarter.

Cipla Ltd. is trading below its 30 day SMA of 1441.8

Cipla Ltd.

08 Jul 2026

1420.00

1.23%

Cipla Ltd – Q1FY27 Preview:

Accumulate: Cipla Ltd.

Target

Deven Choksey

We expect revenue to grow 2.4% YoY to INR 71,269 Mn, supported by steady growth across the India and One Africa businesses.

Cipla Ltd. has an average target of 1552.89 from 9 brokers.

Cipla Ltd.

14 May 2026

1420.00

1.23%

Cipla (HOLD): Mixed Earnings; exciting set of new products awaited

Hold: Cipla Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 1%/11%30% below estimates. Gross Margin reported 360 bps above; EBITDA Margin 176 bps below estimates

Cipla Ltd. is trading below its 30 day SMA of 1441.8

Cipla Ltd.

14 May 2026

1420.00

1.23%

Cipla (CIPLA IN) Q4FY26 Result Update Weak US revenues, timely launches will be key Accumulate

Accumulate: Cipla Ltd.

Target

Prabhudas Lilladhar

Muted US sales: CIPLA's Q4FY26 revenues declined 3% YoY to INR 65.4bn, below our estimates. Domestic formulation reported strong growth of 15% YoY. Key therapies such as Respiratory, Urology, Anti diabetic and Cardiac outpaced the market. US sales contribution from gRevlimid and supply issues in gLanreotide. One Africa business reported growth of 21% YoY; whereas EM + EU markets were down 8% YoY. Healthy GMs, EBITDA miss: GMs stood at 66%, down 185bps YoY but up 280bps QoQ. CIPLA reported EBITDA of INR 9.5bn; down 38% YoY; 7% below our estimates. OPM up 19% YoY and 3% QoQ. Ex R&D cost other expenses were up 6% YoY. Resultant PAT...

Cipla Ltd. is trading above its 200 day SMA of 1396.7

Cipla Ltd.

14 May 2026

1420.00

1.23%

Cipla Ltd.

Buy: Cipla Ltd.

Target

ICICI Direct

The revenues were largely in line except US where intensity was tad higher which was offset by higher growth in other geographies. The management is confident of better performance from India and US in the ensuing year with better performance in second half. FY26 was year of some consolidation mainly due to genericization of gRevlimid and problems in some of its Key Products in US geographies. Going forward, the management momentum to really accelerate in the US from H2FY27 with an aspiration to reach US$ 1 billion annual revenue run rate by exit quarter...

Number of FII/FPI investors decreased from 964 to 917 in Jun 2026 qtr

Cipla Ltd.

24 Apr 2026

1420.00

1.23%

Launches to address concern on US growth; valuation attractive

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Cipla’s recent product approval of gOfev and gVentolin from the USFDA is likely to start allaying concerns arising on its US growth post the discontinuation of Lanreotide, loss of exclusivity in gRevlimid and regulatory issues at key plants in India.

Number of FII/FPI investors decreased from 964 to 917 in Jun 2026 qtr

Is Cipla Ltd. worth buying?

650 Votes:

Buy 75.85%

Sell 13.54%

Hold 10.62%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf